Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports. A number of other research ...
Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from an overweight rating to an equal weight rating in a report issued on Thursday, MarketBeat.com reports ...
On Thursday, the Food and Drug Administration approved the non-opioid pain relievers from Vertex Pharmaceuticals, a new ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...